News

The partnership will engage in the discovery and development of next-generation bispecific immunotherapies for multiple cancer indications. Under the deal, Immatics will secure an upfront fee of $54m

As of August 2018, a new Logistics Hub in Santiago de Chile will benefit the growing pharma & healthcare industry in South America with a dedicated warehousing solution.

Visterra is engaged in the development of advanced antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Otsuka Pharmaceutical representative director and president

Idera said that majority of its stockholders voted in favor of the adoption of the merger agreement with BioCryst. BioCryst will pay $6m as transaction-related expenses to Idera,

As per the cash-cum stock deal signed in early May, the Japanese pharma company offers to pay $30.33 in cash for each Shire share in addition to either

The agency said that the recall pertains to medicines which use valsartan supplied by China-based Zhejiang Huahai Pharmaceuticals. It revealed that the review was launched after Zhejiang Huahai

Apart from the approval of the UK marketing authorisation application, Alliance Pharma has also received the agency’s nod to market the prescription nausea drug under the brand name

The companies have also announced research collaboration for the development of five additional gene therapy products in neurological disorders. Benitec’s silence-and-replace gene therapy technology has been designed to deliver a

The Pennsylvania-based cannabinoid-based drug developer reported that the drug, which is delivered via a transdermal patch, could not achieve the target blood levels of 5 to 15ng/ml THC